CAJ | 학술논문

目的观察晚期非小细胞肺癌患者表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)获得性耐药后应用化疗序贯EGFR-TKI治疗的效果及安全性.方法回顾分析复旦大学附属中山医院2006年5月至2014年4月收治的36例晚期非小细胞肺癌EGFR-TKI获得性耐药患者的临床特征,其中化疗序贯EGFR-TKI组27例,单用化疗组9例,比较两组的近期疗效、无进展生存时间和不良反应.结果化疗序贯EGFR-TKI组和单用化疗组的客观缓解率分别为7.4％和0(P=0.557);疾病控制率分别为81.5％和44.4％ (P =0.046);中位无进展生存时间分别为3.3和2.5个月(P=0.587).两组不良反应的发生率差异无统计学意义(P＞0.05).结论化疗序贯EGFR-TKI组的疾病控制率高于单用化疗组,但并没有带来生存获益.序贯治疗的不良反应可以接受.
목적 관찰만기비소세포폐암환자표피생장인자수체-락안산격매억제제(EGFR-TKI)획득성내약후응용화료서관EGFR-TKI치료적효과급안전성.방법 회고분석복단대학부속중산의원2006년5월지2014년4월수치적36례만기비소세포폐암EGFR-TKI획득성내약환자적림상특정,기중화료서관EGFR-TKI조27례,단용화료조9례,비교량조적근기료효、무진전생존시간화불량반응.결과 화료서관EGFR-TKI조화단용화료조적객관완해솔분별위7.4％화0(P=0.557);질병공제솔분별위81.5％화44.4％ (P =0.046);중위무진전생존시간분별위3.3화2.5개월(P=0.587).량조불량반응적발생솔차이무통계학의의(P＞0.05).결론 화료서관EGFR-TKI조적질병공제솔고우단용화료조,단병몰유대래생존획익.서관치료적불량반응가이접수.
Objective To explore the therapeutic efficacy and safety of chemotherapy subsequent epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced non-small cell lung cancer (NSCLC) patients with EGFR-TKI acquired resistance.Methods The clinical features of 36 advanced NSCLC patients with EGFR-TKI acquired resistance from Affiliated Zhongshan Hospital,Fudan University between May 2006 and April 2014 were retrospectively reviewed.Twenty-seven of them received chemotherapy subsequent EGFR-TKI and another 9 chemotherapy alone.The short-term response,progression-free survival and side effects of two groups were compared.Results The objective response rates of chemotherapy subsequent EGFR-TKI and chemotherapy alone groups were 7.4％ and 0 (P =0.557),disease control rates 81.5％ and 44.4％ (P =0.046) and median progression-free survival 3.3 and 2.5 months,respectively (P =0.587).No significant differences existed in the rates of side effects between two groups (P ＞ 0.05).Conclusions The disease control rates of chemotherapy subsequent EGFR-TKI group are higher than chemotherapy alone group,but there is no survival benefit.And the side effects of subsequent therapy are tolerable.